New Weight-Loss Medication GLP-3 Gains Attention
Recently, a new term has been making waves in the weight-loss world: “GLP-3.” This term refers to a promising new type of drug that goes beyond the well-known GLP-1 medications, claiming to improve weight loss results by targeting multiple hormones.
What is GLP-1?
GLP-1 (glucagon-like peptide-1) medicines mimic a hormone that helps manage blood sugar and hunger. Now, the focus is shifting to GLP-3 drugs, which are designed to act on three hormones: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon. One of the leading examples of this new generation of medication is called retatrutide, developed by Eli Lilly.
Impressive Trial Results
A recent study published in the New England Journal of Medicine showcased encouraging results from a phase 2 trial of retatrutide. Participants who received a 12 mg injection weekly lost an average of 24.2% of their body weight over 48 weeks. After the trial ended, many continued to shed pounds.
Side Effects
The side effects seem to mirror those of GLP-1 medications, with common issues being nausea, vomiting, and diarrhea. Some participants also experienced an increase in heart rate, depending on the dosage.
How GLP-3 Works Differently
What sets retatrutide apart is its ability to mimic three hormones instead of just one. GLP-1 and GIP signal the pancreas to release insulin after meals and slow digestion, which makes you feel full. Glucagon, the third hormone, ramps up metabolism and helps the body utilize fat for energy while keeping blood sugar levels stable.
Significant Improvements for Participants
In a phase 3 trial called TRIUMPH-4, individuals dealing with obesity and knee arthritis who took retatrutide experienced an average weight loss of 71.8 pounds, or 28.7%, in just 68 weeks. The medication also significantly lowered pain scores related to osteoarthritis, helping many participants enjoy a better quality of life.
Future of GLP-3 Medications
With seven more phase 3 trials slated to conclude in 2026, retatrutide could gain FDA approval as early as 2027. Experts note that this new drug may also find applications for conditions like type 2 diabetes, kidney disease, and metabolic disorders.
Expert Opinions
Dr. Marc Siegel, a medical analyst, highlighted the potential benefits of these new medications, predicting they could significantly aid in weight loss and reduce complications tied to obesity. He emphasized, however, that users should be closely monitored due to potential long-term safety issues.
Final Thoughts
Though GLP-3 drugs like retatrutide show great promise, it’s crucial for patients to work with healthcare professionals experienced in managing weight-loss medications. As research continues, the hope is that these innovative drugs can offer real solutions to those struggling with obesity and related health conditions.
